A study from Informa Pharma Intelligence and YouGov concluded that vaccine hesitancy remains a significant hurdle in the U.S. A separate study published in JAMA indicates vaccine hesitancy is falling. Specifically, the number of people who were suspicious about COVID-19 vaccines fell from 46% in October 2020 to 35% in March 2021.

Conversely, the Informa-YouGov survey from April 21 and 22 concluded that 23% of Americans were vaccine-hesitant. The study had 1,327 adult participants.

While approximately half of the U.S. public has received at least one vaccine dose, vaccinating the remainder of the eligible population could be a hurdle.

But the recent data from the Informa-YouGov survey indicate that achieving President Biden’s goal of providing at least one vaccine dose to 70% of the American adults by July 4 is at least feasible.

Another factor that could bode well for mass vaccination is the availability of more data showing COVID-19 vaccines are safe and effective in children under 18. A total of 28% of American parents would be more likely to vaccinate their children if they had access to convincing safety and efficacy data for that demographic.

The potential introduction of new vaccines could also influence the public’s perception of COVID-19 vaccines. At present, there is a clear preference for the Pfizer-BioNTech vaccine, which is the top choice of 42% of Americans. The Moderna vaccine is the number one pick of 25% of Americans, while the Johnson & Johnson vaccine is the top choice of 9%.

Some 22% of Americans would be more likely to take a new COVID-19 vaccine if they believed clinical studies showed it to be more effective against SARS-CoV-2 variants.

 

---

Filed Under: clinical trials, Drug Discovery, Infectious Disease
Tagged With: BioNTech, coronavirus, covid-19, COVID-19 vaccine, COVID-19 vaccine trial, COVID-19 vaccines, Informa Pharma Intelligence, Johnson & Johnson, Moderna, Pfizer, YouGov
 

---